Dr. Reddy's Labs - U.S., Europe To Drive Growth: Nirmal Bang

Nirmal Bang Report

We hosted the management of Dr. Reddy’s Laboratories Ltd. to gain insights into the current business outlook. New launches in the U.S. and the Europe are expected to drive growth.

Growth in the U.S. is being led by both base business as well as limited volume products, with a mix of complex and non-complex filings. Emerging markets strategy focuses on brand building and leveraging products developed for the U.S. and Europe.

In India, emphasis is on core business and innovation in three areas: innovative assets, consumer health and digital. Strong growth is expected in the Gx segment in the near term on the back of Revlimid, stable base business performance and key launches in the developed markets. The company is actively spending on complex products, Biosimilars and Horizon II.

We maintain 'Accumulate' on Dr. Reddy's with a revised target price of Rs 6,553, valuing it at 24 times price-to-earning on Dec-25E base earnings per share of Rs 264 and net present value of Rs 212 for the Revlimid opportunity.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.